Adaptive Biotechnologies Corp (ADPT)
NASDAQ:ADPT
Want to see ADPT full AI Analyst Report?
ADPT Stock Chart & Stats
$14.47
-$0.27(-3.80%)
At close: 4:00 PM EST
$14.47
-$0.27(-3.80%)
Day’s Range― - ―
52-Week Range$8.38 - $20.76
Previous CloseN/A
Volume480.81K
Average Volume (3M)2.18M
Market Cap
$2.31B
Enterprise Value$2.22B
Total Cash (Recent Filing)$226.98M
Total Debt (Recent Filing)$280.58M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Aug 05, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding153,981,570
10 Day Avg. Volume1,842,389
30 Day Avg. Volume2,178,321
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)11.26
Price to Sales (P/S)8.90
P/FCF Ratio-50.34
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue8.02
Enterprise Value/Gross Profit10.81
Enterprise Value/Ebitda-59.64
Forecast
1Y Price Target
$20.67Price Target Upside42.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.48
Revenue Forecast (FY)$282.36M
Bulls Say, Bears Say
Bulls Say
Guidance And Revenue OutlookGuidance that exceeded analyst expectations signals stronger test volume growth and potential for higher average selling prices, supporting revenue upside.
Profitability And Cash Flow TrajectoryProgress toward positive adjusted profitability and organizational free cash flow reduces business risk and supports the case for a sustained valuation multiple.
Strategic Partnerships And Data MonetizationA licensing agreement with a major pharmaceutical company validates the immune receptor data strategy and creates additional revenue opportunities from data licensing.
Bears Say
Execution Risk On Product ExpectationsHeightened expectations for the minimal residual disease business and the need for margin improvement raise execution risk that could weigh on the stock if growth or margins disappoint.
Leverage And Balance Sheet ConstraintsElevated net debt and rising leverage increase financial risk and may limit strategic flexibility for investments or acquisitions.
Adaptive Biotechnologies News
ADPT FAQ
What was Adaptive Biotechnologies Corp’s price range in the past 12 months?
Adaptive Biotechnologies Corp lowest stock price was $8.38 and its highest was $20.76 in the past 12 months.
What is Adaptive Biotechnologies Corp’s market cap?
Adaptive Biotechnologies Corp’s market cap is $2.31B.
When is Adaptive Biotechnologies Corp’s upcoming earnings report date?
Adaptive Biotechnologies Corp’s upcoming earnings report date is Aug 05, 2026 which is in 90 days.
How were Adaptive Biotechnologies Corp’s earnings last quarter?
Adaptive Biotechnologies Corp released its earnings results on May 05, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.16 by $0.03.
Is Adaptive Biotechnologies Corp overvalued?
According to Wall Street analysts Adaptive Biotechnologies Corp’s price is currently Undervalued.
Does Adaptive Biotechnologies Corp pay dividends?
Adaptive Biotechnologies Corp does not currently pay dividends.
What is Adaptive Biotechnologies Corp’s EPS estimate?
Adaptive Biotechnologies Corp’s EPS estimate is -0.14.
How many shares outstanding does Adaptive Biotechnologies Corp have?
Adaptive Biotechnologies Corp has 153,981,570 shares outstanding.
What happened to Adaptive Biotechnologies Corp’s price movement after its last earnings report?
Adaptive Biotechnologies Corp reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.16. Following the earnings report the stock price went up 4.717%.
Which hedge fund is a major shareholder of Adaptive Biotechnologies Corp?
Currently, no hedge funds are holding shares in ADPT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adaptive Biotechnologies Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.67 (42.82% Upside)
$20.67 (42.82% Upside)
Blogger Sentiment
Neutral
ADPT Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 3.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $214.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
97.40%
12-Months-Change
Fundamentals
Return on Equity
-30.00%
Trailing 12-Months
Asset Growth
78.73%
Trailing 12-Months
Company Description
Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
ADPT Company Deck
ADPT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call portrays a company with strong, broad-based MRD momentum: double-digit revenue growth, volume records, margin expansion, a raised MRD revenue guide, growing backlog, and improving MRD profitability. Challenges are concentrated in the immune medicine business (declining revenue and losses), company-level net loss and elevated operating expenses, milestone lumpiness, and reimbursement/regulatory uncertainty. Taken together the positives—notably durable clinical adoption, pricing gains, margin improvement, a large and growing backlog, and a solid cash position—outweigh the negatives, which are largely isolated or acknowledged with mitigations in progress.View all ADPT earnings summariesADPT Stock 12 Month Forecast
Average Price Target
$20.67
▲(42.82% Upside)
Technical Analysis
Immunovant
―
Arcutis Biotherapeutics
―
Harmony Biosciences Holdings
―
Immunocore Holdings
―
Recursion Pharmaceuticals
―
Ownership Overview
3.71% Insiders
23.80% Mutual Funds
4.94% Other Institutional Investors
51.21% Public Companies and
Individual Investors